Independent Data Monitoring Committee Recommends Discontinuation Of The Phase 3 Study of Prostvac In Metastatic Prostate Cancer

It was announced yesterday that an independent Data Monitoring Committee (DMCB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 PROSPECT study of PROSTVAC® in men with metastatic castration-resistant prostate cancer (mCRPC) is futile. 

Although not yet official, the trial of Prostvac alone will probably be discontinued.  Bavarian Nordic, the company that is sponsoring the trial has made an indication that they might continue and use Prostvac in combination treatment trials.

This is disappointing news for all of us.  There are other immunotherapies still in clinical trials for the treatment of men with advanced prostate cancer.  We now will just have to continue waiting for other results.

Joel T. Nowak, MA, MSW wrote this Post.  Joel is the CEO/Executive Director of Cancer ABCs.  He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and Appendiceal Cancer a rare cancer.